Head-to-head · Value Score
bmiMD vs Mevo Health
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, Mevo Health a 72. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameMevo Health
#198 · Grade C · Watch List
Est. first month
From $199/mo (all doses, compounded)
Save ~85% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 72 — an est. $99/mo first month, with no teaser step-up baked in. Mevo Health isn't out of it: Shoppers who want physician-network GLP-1 in injection and oral-tablet forms.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | Mevo Health |
|---|---|---|
| Value Score | 89 (A) | 72 (C) |
| Est. first month | $99/mo | From $199/mo (all doses, compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (all doses, compounded) |
| Tirzepatide | $139/mo | From $259/mo (all doses, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
Mevo Health
Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.
Why it's a deal
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
The fine print
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to Mevo Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.